The authors concluded that the loss of either or both SMARCA2 and SMARCA4 led to the progression of lung adenocarcinoma into a solid-predominant tumor and to epithelial–mesenchymal transition, with loss of the bronchial epithelial phenotype [7]. Here, SMARCA2 is linked to lung adenocarcinoma.